References
- Marras C, Beck JC, Bower JH, et al. Prevalence of Parkinson’s disease across North America. NPJ Parkinsons Dis. 2018;4:21.
- Parkinsons Foundation. Prevalence and incidence. Available from: https://www.parkinson.org/understanding-parkinsons/statistics/prevalence-incidence
- Factor SA, Scullin MK, Sollinger AB, et al. Cognitive correlates of hallucinations and delusions in Parkinson’s disease. J Neurol Sci. 2014;347(1-2):316–321.
- Ffytche DH, Creese B, Politis M, et al. The psychosis spectrum in Parkinson disease. Nat Rev Neurol. 2017;13(2):81–95.
- Aarsland D, Larsen JP, Tandberg E, et al. Predictors of nursing home placement in Parkinson’s disease: a population-based, prospective study. J Am Geriatr Soc. 2000;48(8):938–942.
- Chen JJ, Hua H, Massihi L, et al. Systematic literature review of quetiapine for the treatment of psychosis in patients with parkinsonism. J Neuropsychiatry Clin Neurosci. 2019;31(3):188–195.
- Hermanowicz N, Edwards K. Parkinson’s disease psychosis: symptoms, management, and economic burden. Am J Manag Care. 2015;21(10 Suppl):s199–s206.
- Connolly B, Fox SH. Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson’s disease. Neurotherapeutics. 2014;11(1):78–91.
- Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson’s disease: a review. Drugs Aging. 2008;25(8):665–682.
- Chen JJ. Treatment of psychotic symptoms in patients with Parkinson disease. Ment Health Clin. 2017;7(6):262–270.
- Acadia Pharmaceuticals. Nuplazid® (pimavanserin) prescribing information. San Diego, CA: Acadia Pharmaceuticals Inc.; 2018.
- By the American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63(11):2227–2246.
- Hawkins T, Berman BD. Pimavanserin: a novel therapeutic option for parkinson disease psychosis [published correction appears in Neurol Clin Pract. 2017 Aug;7(4):282]. Neurol Clin Pract. 2017;7(2):157–162.
- Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial [published correction appears in Lancet. 2014 Jul 5;384(9937):28]. Lancet. 2014;383(9916):533–540.
- Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review [published correction appears in Mov Disord. 2019 May;34(5):765]. Mov Disord. 2019;34(2):180–198.
- Kumar S, Rashid N, Doshi D, et al. ER visits and hospitalizations among patients treated with pimavanserin or other-AAPs for Parkinson’s disease psychosis: analysis of Medicare beneficiaries [abstract]. Mov Disord. 2022;37(suppl 1). Available from: https://www.mdsabstracts.org/abstract/er-visits-and-hospitalizations-among-patients-treated-with-pimavanserin-or-other-aaps-for-parkinsons-disease-psychosis-analysis-of-medicare-beneficiaries/
- Sewell DD, Jeste DV, Atkinson JH, et al. HIV-associated psychosis: a study of 20 cases. San Diego HIV neurobehavioral research center group. Am J Psychiatry. 1994;151(2):237–242.
- Collins RL, Beckett MK, Burnam MA, et al. Mental health and substance abuse issues among people with HIV: lessons from HCSUS. Santa Monica (CA): RAND Corporation; 2007. Available from: https://www.rand.org/pubs/research_briefs/RB9300.html.
- Substance Abuse and Mental Health Services Administration. Co-occurring disorders and other health conditions; 2022 Apr 21 [updated 2022 Apr 21; cited 2022 Jul 29]. Available from: https://www.samhsa.gov/medication-assisted-treatment/medications-counseling-related-conditions/co-occurring-disorders
- Sterling S, Chi F, Hinman A. Integrating care for people with co-occurring alcohol and other drug, medical, and mental health conditions. Alcohol Res Health. 2011;33(4):338–349.
- Rajagopalan K, Rashid N, Kumar S, et al. Health care resource utilization patterns among patients with Parkinson’s disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics. J Med Econ. 2023;26(1):34–42.
- Pringsheim T, Gardner DM. Dispensed prescriptions for quetiapine and other second-generation antipsychotics in Canada from 2005 to 2012: a descriptive study. CMAJ Open. 2014;2(4):E225–E232.
- Debernard KAB, Frost J, Roland PH. Quetiapine is not a sleeping pill. Kvetiapin er ikke en sovemedisin. Tidsskr nor Laegeforen. 2019;139(13). DOI:10.4045/tidsskr.19.0205
- Duncan D, Cooke L, Symonds C, et al. Quetiapine use in adults in the community: a population-based study in Alberta, Canada. BMJ Open. 2016;6(3):e010861.
- Diehr P, Yanez D, Ash A, et al. Methods for analyzing health care utilization and costs. Annu Rev Public Health. 1999;20:125–144.
- Alipour-Haris G, Armstrong MJ, Okun M, et al. Comparison of pimavanserin versus quetiapine for hospitalization and mortality risk among Medicare beneficiaries with Parkinson’s disease psychosis. Mov Disord Clin Pract. 2023;10(3):406–414.